Defining Progression in Metastatic Kidney Cancer
3 Visualizações
• 06/26/23
0
0
Embutir
administrator
Assinantes
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários